Jomed Cardiac Assist System Is Firm’s Foundation For U.S. Market Growth
This article was originally published in The Gray Sheet
Executive Summary
Jomed's Reitan catheter pump (RCP) is aimed at growing the Swiss firm's U.S. market presence in addition to expanding the leading European stent supplier's cardiovascular product line
You may also be interested in...
Jomed Valve Repair Sale To Edwards Could Presage Additional Divestitures
Edwards Lifesciences will combine Jomed's catheter-based mitral heart valve repair technology with its own percutaneous R&D program under a two-pronged strategy to address a potential $800 mil. global market for the procedure
Jomed Valve Repair Sale To Edwards Could Presage Additional Divestitures
Edwards Lifesciences will combine Jomed's catheter-based mitral heart valve repair technology with its own percutaneous R&D program under a two-pronged strategy to address a potential $800 mil. global market for the procedure
Thoratec HeartMate
Firm expects FDA to grant PMA supplement approval of the left-ventricular assist device as an alternative to transplant in the near future. "Based on our most recent discussions with the FDA" and upcoming labeling discussions, "we continue to have a great deal of confidence that we are close to receiving approval for destination therapy," President and CEO Keith Grossman reports during an Oct. 23 earnings call. Thoratec also expects a PMA supplement filing for the IVAD implantable ventricular assist device in the first half of 2003...